Going KiNativ(TM): ActivX Biosciences, Inc. Publishes Landmark Article on Kinase Profiling
7/6/2011 9:46:30 AM
More...
|
ActivX Biosciences, Inc. Head Receives Distinguished Scientist Award
1/4/2010 9:37:45 AM
More...
|
ActivX Biosciences, Inc. Announces Positive Phase Ib and IIa Clinical Trial Results for KRP-104, a Flexible Dosing DPP-4 Inhibitor for Type 2 Diabetes
8/21/2008 8:58:46 AM
More...
|
ActivX Biosciences, Inc. Launches Breakthrough Kinase Platform, KiNativ
3/21/2007 10:12:55 AM
More...
|
ActivX Biosciences, Inc./Kyorin Pharmaceutical Co., Ltd. Begins First U.S. Phase I Study For Novel Anti-Diabetic Drug
3/15/2006 10:19:54 AM
More...
|
ActivX Biosciences, Inc. Announces Expansion Of Strategic Collaboration Agreement With Pfizer Inc. (PFE) With Multiple Discovery And Developmental Stage Projects
3/14/2006 10:42:13 AM
More...
|
ActivX Biosciences, Inc. Announces Expansion Of Strategic Collaboration Agreement With Pfizer Inc. (PFE) With Multiple Discovery And Developmental Stage Projects
10/19/2005 5:12:40 PM
More...
|
ActivX Biosciences, Inc. Announces Closing Of Acquisition By Kyorin Pharmaceutical Co., Ltd.
10/19/2005 5:12:36 PM
More...
|
Kyorin Pharmaceutical Co., Ltd. To Acquire ActivX Biosciences, Inc.
10/19/2005 5:12:22 PM
More...
|
ActivX Biosciences, Inc. Appoints James A. Schoeneck Chief Executive Officer; Dr. John W. Kozarich Assumes Role Of President And Chief Research And Development Officer
10/19/2005 5:10:48 PM
More...
|
|